Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell inks research collaboration deal with European biopharma BioNTech

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors
cancer cells under a microscope
BioNTech recently raised US$270mln as part of a Series A funding

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer.

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.

READ: Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

Moditope is a new class of potentially potent immunotherapy agents which stimulate the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

To get a bit scientific, Moditope stimulates the production of the CD4+ T cells using tumour-associated peptide epitopes which allow the activated T cells to seek out and kill tumour cells that would otherwise have been hidden from the immune system.

Once the initial studies have been completed, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Scancell’s Modi-1 epitopes.

‘Great potential’

“We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer,” Scancell’s chief scientific officer Lindy Durrant.

READ: Scancell on the lookout for partners after year of “significant progress”

“Pre-clinical data from our Moditope platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition.

“We believe that this, combined with BioNTech's engineered T cells specific to Moditope epitopes, could have great potential as a novel immunotherapy.”

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use